-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated ...
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...
ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization ...
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, ...
-- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results-- The CHASE Phase 2b trial is a multicenter, ...
Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...
When measuring your work and success and seeking a deep understanding of ongoing processes, noting will be more important than knowing your Key Performance Indicators (KPIs) and how to deal with them.